Executive Summary
PARTNER 3's 7-year readout — the deepest look yet at TAVR versus SAVR in low-risk patients — landed at ACC today and reset the durability conversation just as CMS issued its final TAVR NCD decision memo (CAG-00430R2). The regulatory pathway now clarifies coverage precisely when the seven-year signal — critical because ESC 2025 already pushed the TAVI age threshold to 70 while ACC/AHA held at 65 — matters most for lifetime-management decisions. GDF-15 outperformed NT-proBNP for predicting death after tricuspid TEER in a BMC Cardiovascular Disorders cohort, adding to a growing case that we are risk-stratifying T-TEER patients with the wrong biomarker, which tightens the case for systemic-disease-burden gating before intervention.
- PARTNER 3 delivers 7-year TAVR vs SAVR data in low-risk patients — the longest randomized readout yet in this population (ACC).
- CMS finalizes CAG-00430R2 with a decision memo restructuring TAVR coverage and volume requirements (CMS).
- GDF-15 outperforms NT-proBNP for predicting 12-month mortality after tricuspid TEER (AUC 0.823 vs 0.535, N=84, single-center) (BMC Cardiovascular Disorders).
- Transapical TAVR retains a defined role in hybrid coronary-valve treatment despite the transfemoral shift (Annals of Thoracic Surgery).
- Edwards INSPIRIS RESILIA valve-in-valve surveillance study (NCT04902053) is SUSPENDED — a data flag for a valve marketed on future ViV compatibility (ClinicalTrials.gov).
What to watch: Medtronic's fiscal Q1 earnings on September 1 will surface the first structural heart commentary tested against the new CMS TAVR NCD.
Aortic Valve (TAVR/TAVI)
[NOTABLE] PARTNER 3 at 7 years is the durability readout the low-risk debate has been waiting for. The ACC-published 7-year outcomes arrive at the exact fault line between guidelines: ESC 2025 recommends TAVI for tricuspid AS patients ≥70 (Class I), while ACC/AHA 2020 holds SAVR-preferred at <65 and puts 65-80 in shared decision-making. The 65-70 age band — where a 7- to 10-year durability gap becomes clinically relevant — is precisely where PARTNER 3 patients are aging into re-intervention territory now. Any structural valve deterioration or reintervention signal at year 7 undercuts the ESC's more aggressive age-threshold move; equivalent durability strengthens it.
Surgical counterpoint: current guidelines still favor SAVR when lifetime management requires future valve-in-valve feasibility, and THV explantation carries 12-17% mortality per ESC 2025. An updated meta-analysis of lower-risk RCTs showed a 20% hazard reduction for all-cause death with TAVR at 5 years (HR 0.80, 95% CI 0.66-0.97) — but disappeared when intermediate-risk trials were excluded, per an accompanying editorial framing. Transapical TAVR retains relevance in hybrid coronary-valve cases where transfemoral access is precluded — a niche indication but one the field has quietly under-reported as TF dominance grew.
Mitral Valve (MitraClip, PASCAL, TMVR)
Valve-in-valve TMVR remains a technically demanding rescue, and a case report in a 75-year-old with a failed Pericarbon More bioprosthesis illustrates the underappreciated hazard: transseptal dilation created an abrupt left-to-right shunt with hemodynamic compromise before mitral obstruction was relieved. Rapid balloon dilation of the stenotic bioprosthesis rescued the case; a 26-mm SAPIEN 3 followed with a mean gradient of 3.5 mmHg and 2-year durability. Single case, no comparator, but the sequencing lesson is real — septum first while the mitral stays tight is a physiologic trap. ACC/AHA 2020 rates ViV TMVR reasonable for high-risk patients with degenerated bioprostheses; ESC 2025 aligns.
A new Chinese trial (NCT07744035, N=384) will randomize combined TEER plus catheter ablation for atrial functional MR — the first prospective test of the ESC 2025 atrial SMR management pathway that was upgraded to a formal entity this year. OCEAN-Mitral registry data already suggest TEER benefit in atrial FMR (HR 0.65 vs medical therapy), but a randomized signal is what the guideline framework needs.
Tricuspid Valve (TriClip, TTVR)
NT-proBNP is a poor risk-stratifier for tricuspid TEER, and the Schlegl et al. cohort (N=84, single-center, exploratory) puts numbers on it: baseline NT-proBNP achieved AUC 0.535 for 12-month mortality — essentially chance. GDF-15 hit AUC 0.823, suPAR 0.742. The mechanistic read is that patients dying after T-TEER are dying from systemic inflammation and multi-organ dysfunction, not ventricular stretch — which is why a biomarker built for HF forward-flow physiology fails here. The finding is exploratory and needs multicenter replication, but it aligns with the too-late-referral problem both ACC/AHA and ESC have flagged.
Surgical counterpoint: ESC 2025 upgraded transcatheter tricuspid treatment to Class IIa but simultaneously upgraded surgical TV repair for symptomatic severe primary TR to Class I. ACC/AHA 2020 pre-dates the transcatheter TR evidence entirely. GDF-15-based selection could push the field toward earlier intervention in appropriate patients and away from those already systemically decompensated — the group in which STS/ACC TVT Registry data still show meaningful 30-day mortality (3.1%) even with 98.4% technical success.
Surgical vs. Transcatheter Comparisons
Today's PARTNER 3 7-year readout is the head-to-head. No separate surgical comparator study landed. The relevant surgical context: long-term data in patients aged 50-70 continue to favor mechanical over biological aortic prostheses on survival, with severe patient-prosthesis mismatch driving the worst outcomes. This is the population the ESC's age-70 threshold moves into TAVI territory, and where lifetime management planning matters most.
Preprint Highlights
Nothing structural-heart-relevant in today's preprint feed — the Stelpaviricetes ribovirian diversity preprint on bioRxiv is unrelated to valve disease.
Regulatory & Policy
[NOTABLE] CMS finalized the TAVR NCD with two parallel documents: CAG-00430R and CAG-00430R2. Site-volume requirements, heart team composition, and coverage-with-evidence-development structure are the levers to watch — every prior NCD revision has reshuffled which programs stay competitive. The proposed decision memo released alongside signals CMS is retaining the multi-disciplinary heart team requirement — reinforcing the surgical-interventional partnership that ESC 2025 also codified. A separate blood thinner recall reported by Cardiovascular Business after failed dissolution testing bears on periprocedural anticoagulation planning; specifics on agent and lot pending.
Industry & Market
Edwards is trading the tension between long-term structural growth thesis and legal overhang. Yahoo Finance ran a piece on Edwards' "growth runway competitors may struggle to match" the same day the securities fraud class action final deadline hit. The clinical read: PARTNER 3's 7-year data is Edwards' data — durability is the moat. If the 7-year signal holds, the growth runway narrative is defensible. If SVD or reintervention creeps in, the low-risk expansion thesis erodes.
Financial Analysis
The market is pricing PARTNER 3 durability into Edwards (+14.7% over 6 months) while punishing Boston Scientific (-36.8%) on execution issues that predate today's news. The CMS TAVR NCD finalization is net-positive for Edwards and Medtronic on regulatory certainty, but volume-threshold provisions could concentrate share at high-volume centers — a structural tailwind for the incumbents. Anteris (+47.3%) continues to trade on DurAVR clinical momentum despite being pre-revenue; the single analyst target of AUD $13.00 is a thin consensus. The Edwards securities class action deadline today is not new information but resurfaces on the day of the definitive PARTNER 3 readout — the timing tests whether long-term valve narrative overwhelms nearer-term legal risk.
Valve Industry Stocks
Edwards Lifesciences (EW)
- Close: $89.60 (+0.88%); 6-month: +14.72%
- Market cap: $51.6B; P/E trailing 53.0, forward 26.5; beta 0.85
- 52-week range: $72.30 - $96.29
- Analyst target: $100.96 (26 analysts, buy)
- Next earnings: October 29 (EPS est $0.74, revenue est $1.68B)
- Trading near 52-week highs into PARTNER 3 7-year readout; securities class action deadline today is short-term overhang but does not change SAPIEN durability narrative.
Medtronic (MDT)
- Close: $86.20 (-0.55%); 6-month: -14.82%
- P/E trailing 23.2, forward 13.4; beta 0.57
- 52-week range: $73.31 - $106.33
- Analyst target: $98.44 (25 analysts, buy)
- Next earnings: September 1 (EPS est $1.39, revenue est $9.55B) — first structural-heart commentary against the new CMS NCD.
Abbott (ABT)
- Close: $105.46 (-1.55%); 6-month: -2.02%
- Market cap: $182.5B; P/E trailing 33.7, forward 17.4; beta 0.58
- Analyst target: $118.42 (24 analysts, buy)
- Next earnings: October 14
- TriClip momentum from ESC 2025 Class IIa upgrade is core to the structural heart thesis; GDF-15 biomarker findings could reshape patient selection.
Boston Scientific (BSX)
- Close: $49.09 (+1.36%); 6-month: -36.77%
- Market cap: $71.1B; P/E trailing 19.6, forward 14.3; beta 0.57
- Analyst target: $62.69 (29 analysts, buy)
- Next earnings: October 21
- Substantial six-month drawdown reflects competitive dynamics in structural heart and broader portfolio pressures.
Anteris Technologies (AVR.AX)
- Close: AUD $11.49 (-0.09%); 6-month: +47.31%
- Market cap: AUD $1.1B; forward P/E -5.27; beta 0.73
- Analyst target: AUD $13.00 (1 analyst)
- Pre-revenue on DurAVR pivotal trial momentum; thin analyst coverage warrants caution.
The valve industry stock complex is bifurcating: Edwards and Anteris (both pure-play aortic transcatheter) trading up on durability narratives, while diversified Medtronic and Boston Scientific work through broader portfolio pressure. The CMS NCD finalization removes an overhang for the two U.S. TAVR platforms and is neutral-to-positive for near-term volume trajectories.
Clinical Trial Updates
Aortic
- NCT07743697 — Suture vs. combined vascular closure strategies for large-bore access in TAVI. Status: NOT_YET_RECRUITING. Enrollment: 705. Sponsor: University Hospital Basel. ClinicalTrials.gov. Aligned with recent registry data showing plug-based closure achieved 99.8% immediate hemostasis vs 77.7% with suture-based devices — a randomized readout would settle the question.
- NCT04902053 — INSPIRIS RESILIA Aortic Valve, Valve-in-Valve Surveillance. Status changed to SUSPENDED. Enrollment: 50. Sponsor: Edwards Lifesciences. ClinicalTrials.gov. Suspension of a ViV surveillance study for a valve marketed on future ViV compatibility is a flag worth watching — reason for suspension not disclosed in today's update.
Mitral Repair
- NCT07744035 — Ablation with TEER for atrial functional MR and AF. Status: NOT_YET_RECRUITING. Enrollment: 384. Sponsor: Mao Chen. ClinicalTrials.gov. First prospective randomized test of the ESC 2025 atrial SMR combined-therapy pathway (Class IIa).
Next up: PARTNER 3's 7-year manuscript full-text release will drive whether the ESC's age-70 TAVI threshold gets validated or challenged, and Medtronic's September 1 earnings will surface the first structural heart tone against the finalized CMS NCD. — E. Nolan Beckett, MD